By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Fitch Ratings today affirmed its 'BBB' issuer default rating with a stable outlook on Life Technologies.

The New York-based ratings firm said that the rating is supported by a general declining trend in Life Tech's debt leverage over the past three years. It noted that the reduction in leverage is due to a combination of stable operating performance and use of cash for debt reduction.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.